The growth has been driven by an expanding portfolio of over 800 stock-keeping units (SKUs) and a network of over 500 retail stockists
Aqualab, the direct-to-retail division of Laborate Pharmaceuticals India, has crossed the Rs 100 crore revenue mark within three years of operations and now expects to touch Rs 250 crore by the current financial year (FY25–26), the company said in a statement.
The growth has been driven by an expanding portfolio of over 800 stock-keeping units (SKUs) and a network of over 500 retail stockists, with tier-2 and tier-3 markets contributing a rising share of sales. The company said that Aqualab’s growth is in step with national priorities such as Make in India and the government’s production-linked incentive (PLI) push to boost domestic pharma manufacturing.
“Crossing Rs 100 crore in three years demonstrates how quickly the direct-to-retail model is scaling in India. We are now targeting Rs 250 crore by FY25–26, with non-metro markets expected to contribute 42 per cent of incremental growth. Expanding therapeutic categories and strengthening last-mile delivery will remain our key focus areas,” said Arpit Bhatia, Managing Director, Laborate Pharmaceuticals.
Since its inception in 2022, the division has reported consistent year-on-year growth, moving from Rs 76 crore in FY23 to Rs 108 crore in FY24. Aqualab has focused on ensuring affordability and last-mile access, enabling its medicines to reach smaller towns alongside metropolitan centres, as pointed out by the official statement.
The retail pharmacy market, pegged at Rs 18,700 crore in FY24, is projected to touch Rs 31,200 crore by FY32, growing at a compounded annual growth rate of 6.6 per cent on the back of stronger generic penetration, greater health awareness, and organised distribution. Leveraging this momentum, Aqualab is preparing to expand into new categories, add facilities, adopt digital channels, and explore exports.
